| Name | Title | Contact Details |
|---|
Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Using a next generation gene therapy platform, the Ocular BioFactory™, the Company is developing products designed to provide long-term benefit or a functional cure by inducing a sustained expression of a therapeutic protein with a one-time administration in the eye.
Marathon Life Sciences Laboratory Solutions at the Speed of Science Learn more Our Lab Supplies Line Cell Strainer Download Catalogadd to cart Tissue Culture Plates Download Catalog 15/50mL Centrifuge Tubes Download Catalog Petri Dishes Download Catalo...
Nacalai USA is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Alaunos is a clinical stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. With our robust and innovative discovery engine, we strike cancer at its core by engineering cell therapies that target neoantigens arising from genomic mutations. We have developed proprietary, rapid, cost-effective solutions to deliver tumor-specific killer T cells to large cancer patient populations with unmet clinical need. We are based in Houston, TX, home to the largest medical center in the world; and in a state with no state income tax and a low cost of living. For more information about Alaunos, please visit www.alaunos.com. Click on the Careers tab of our web page to join our exciting team and help make a difference in the lives of cancer patients and their families.
Freeline is a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases. We are headquartered in the UK and we also have operations in Germany and the US. Freeline was founded in 2015 and builds upon the pioneering work by our Clinical and Scientific Advisor and Director, Professor Amit Nathwani, Professor of Haematology at UCL. With our liver-based investigational gene therapy technology, we aim to improve the lives of people with chronic systemic diseases and realise the potential of gene therapy treatments.